Sanofi Announces Licensing of Rheumatoid Arthritis Treatment
Sanofi and its specialty care global business unit, Sanofi Genzyme, have announced that the European Commission (EC) has granted marketing authorisation for Kevzara® (sarilumab) in combination with methotrexate (MTX) for the treatment of moderately-to-severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease [...]